|Bid||71.680 x 800|
|Ask||71.690 x 900|
|Day's Range||70.830 - 71.850|
|52 Week Range||63.760 - 88.850|
|PE Ratio (TTM)||7.58|
|Dividend & Yield||2.08 (2.92%)|
|1y Target Est||N/A|
Gilead Sciences remains a value trap because it's still not doing anything with its cash.
Sameul Isaly, founder of one of the world’s most well-known healthcare funds, has made two key moves on Synergy Pharmaceuticals Inc (NASDAQ:SGYP) and Gilead Sciences Inc (NASDAQ:GILD). Isaly is the managing partner of OrbiMed, a global management firm that has assets under management of over $13 billion. Isaly is closely tracked by investors due to his exceptional track record: at the beginning of 2016, Barron’s said he was the only US mutual fund manager to beat the S&P 500 for an incredible 25 straight years.
Gilead Sciences, Inc. (GILD) announced that the CHMP has adopted a positive opinion on the company's application for HCV drug Vosevi.